Drug Trial Radar · NCT03574597
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17,604
Actual
Start
Oct 24, 2018
Primary completion
Jun 21, 2023
Study completion Jun 29, 2023
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.
Conditions
- Overweight
- Obesity
Interventions
SemaglutideDrug
Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
Placebo (semaglutide)Drug
Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal StrokeTime frame: From randomisation (week 0) up to 240 weeks
Locations
833 sites in 42 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
Univ of Alabama Birmingham
Birmingham, Alabama
Healthscan Clinical Trials,LLC.
Montgomery, Alabama
Synexus Clinical Research US, Inc./Tatum
Glendale, Arizona
Synexus Clinical Research
Glendale, Arizona
Synexus Rsch /Cnt Phnx Med C
Phoenix, Arizona
National Heart Institute Cal
Beverly Hills, California
FDRC
Costa Mesa, California
Valley Clinical Trials
Covina, California
Scripps Whittier Diabetes Inst
La Jolla, California
First Valley Medical Group
Lancaster, California
Torrance Clin Res Inst, Inc.
Lomita, California
Long Beach VA healthcare System
Long Beach, California
Angel City Research, Inc.
Los Angeles, California
VAGLAHS Clinical Research Center (CRC)
Los Angeles, California
Riverside University Health System Medical Center
Moreno Valley, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Western University of Health Sciences
Pomona, California
Quartz Hill Walk-in Medical Group, inc.
Quartz Hill, California
TriWest Research Associates
San Diego, California
San Diego Family Care
San Diego, California
Mills-Peninsula Medical Center
San Mateo, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Encompass Clinical Research_Spring Valley
Spring Valley, California
Lundquist Inst-Biomed Innovtn
Torrance, California
Synexus Clinical Research US, Inc._Horsham
Vista, California
University of Colorado Hospital
Aurora, Colorado
Optumcare Colorado Springs, LLC
Colorado Springs, Colorado
Optumcare Colorado Springs
Colorado Springs, Colorado
New West Physicians,Inc.
Golden, Colorado
Optumcare Colorado Springs, LLC_Monument
Monument, Colorado
Bridgeport Hospital
Bridgeport, Connecticut
Yale University School Of Medicine
New Haven, Connecticut
Chase Medical Research LLC
Waterbury, Connecticut
Excel Med Ctr Clinical Trials
Boca Raton, Florida
Bradenton Research Center
Bradenton, Florida
Clearwater Cardiovascular Consultants
Clearwater, Florida
Nature Coast Clin Rsrch_Crystal River
Crystal River, Florida
Florida Premier Cardiology
Delray Beach, Florida
Showing 40 of 833 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.